Highlights Asarina Pharma AB

Equities

ASAP

SE0011641794

Market Closed - Nasdaq Stockholm Other stock markets 11:29:32 2024-05-23 am EDT			5-day change	1st Jan Change
0.806 ^SEK	-0.49%		-4.28%	-8.41%

Feb. 27	Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	23-05-05	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Asarina Pharma Completes Recruitment of Patients to its Phase IIa Clinical Study in Tourette Syndrome	22-10-14	CI
Asarina Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Asarina Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-25	CI
Asarina Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Asarina Pharma AB Announces That `First Patient First Visit' Has Taken Place in Its Phase Ii A Clinical Study in Tourette Syndrome At Bispebjerg University Hospital, Copenhagen	22-02-16	CI
Asarina Pharma Receives Final Approval for Phase IIa Tourette Study	21-12-22	CI
Asarina Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-25	CI
Pmdd Phase Iib Study, Including Post-Hoc Analysis Showing ‘Significant Treatment Effect	21-09-28	CI
Asarina Pharma Announces Administrative Backlog At Public Authority Causes Short-Term Delay in Tourette Study	21-09-16	CI
Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-19	CI
Asarina Pharma Reports Topline Results in Phase IIa Menstrual Migraine Study	21-06-23	CI
The US Patent and Trademark Office Grants Asarina Pharma's Patent for Sepranolone for the Treatment of Tourette, Obsessive-Compulsive Disorder and Pathological Gambling	21-06-08	CI
Asarina Pharma AB Receives Approval of CTA for Phase IIa Tourette Study	21-05-19	CI
Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-18	CI
Asarina Pharma AB Confirms New Preclinical Study That Sepranolone Suppresses Tics in Tourette Syndrome	21-02-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Asarina Pharma AB

Equities

ASAP

SE0011641794

Highlights

Filters